Phase II study of single agent gemcitabine in patients with hormone refractory prostate cancer (HRPC).

被引：0

作者：

Nilsson, S ^{[1
]}

Holmberg, M ^{[1
]}

Ljung, G ^{[1
]}

Pettersson-Skjold, D ^{[1
]}

Blom, R ^{[1
]}

Ullén, A ^{[1
]}

Westberg, R ^{[1
]}

Nilsson, I ^{[1
]}

Lennernas, B ^{[1
]}

机构：

[1] Swedish Prostate Canc Study Grp, Stockholm, Sweden

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4705

引用

页码：432S / 432S

页数：1

共 50 条

[21] Metronomic chemotherapy for hormone refractory prostate cancer (HRPC) [J].

Hoshi, S. ;

Numahata, K. ;

Hoshi, K. ;

Suzuki, K. ;

Ono, K. ;

Sugano, O. ;

Ihidoya, S. ;

Saito, S. ;

Arai, Y. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)

[22] Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer [J].

Di Lorenzo, Giuseppe ;

Autorino, Riccardo ;

Giuliano, Mario ;

Morelli, Emilio ;

Giordano, Antonio ;

Napodano, Giorgio ;

Russo, Aniello ;

Benincasa, Giuseppe ;

D'Armiento, Massimino ;

Altieri, Vincenzo ;

De Placido, Sabino .

UROLOGY, 2007, 69 (02) :347-351

[23] SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) [J].

Romanus, D. ;

Oh, W. K. ;

Cook, F. E. ;

Weeks, J. C. .

VALUE IN HEALTH, 2008, 11 (06) :A487-A487

[24] A randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane (T)-resistant hormone refractory prostate cancer (HRPC). [J].

Rosenberg, JE ;

Kelly, WK ;

Michaelson, MD ;

Wilding, G ;

Hussain, M ;

Gross, M ;

Small, EJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :394S-394S

[25] Randomized phase II study of ixabepilone (Ix) or mitoxantrone and prednisone (MP) in patients with taxane resistant (TR) hormone refractory prostate cancer (HRPC) [J].

Chowdhury, S. ;

Burbridge, S. ;

Harper, P. G. .

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (12) :2064-2070

[26] A phase II study evaluating docetaxel (D) and one day of estramustine phosphate (EMP) in hormone refractory prostate cancer (HRPC). [J].

Sinibaldi, V ;

Carducci, M ;

Moore-Cooper, S ;

Laufer, M ;

Zahurak, M ;

Eisenberger, M .

ANNALS OF ONCOLOGY, 2000, 11 :77-77

[27] Clinical, biochemical (PSA) and radiographic benefit with sunitinib as a single agent in metastatic chemoresistant and hormone-refractory prostate cancer (HRPC) patients [J].

Castellano, D. ;

Gonzalez Larriba, J. ;

Anton Aparicio, L. M. ;

Casinello, J. ;

Grande, E. ;

Esteban, E. ;

Sepulveda, J. ;

Rodriguez, A. ;

Ghanem Canete, I. .

EJC SUPPLEMENTS, 2009, 7 (02) :417-417

[28] A phase I study of estramustine, weekly docetaxel and carboplatin (EDC) chemotherapy in patients with hormone refractory prostate cancer (HRPC). [J].

Oh, WK ;

Hagmann, E ;

Manola, J ;

George, DJ ;

Gilligan, TD ;

Smith, MR ;

Kaufman, DS ;

Kantoff, PW .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :420S-420S

[29] LOW-DOSE KETOCONAZOLE IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS (HRPC): A SINGLE INSTITUTION EXPERIENCE [J].

Romero, J. ;

Rodriguez, A. ;

Villacampa, F. ;

Duarte, J. M. ;

Cabrera, F. ;

Blanco, M. ;

Sepulveda, J. ;

Rodriguez, A. ;

Castellano, D. ;

Leiva, O. .

EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) :132-132

[30] Gemcitabine plus mitoxantrone and prednisone in the palliative treatment of hormone-resistant prostate cancer (HRPC): A phase II study (GOAM 01.01 study) [J].

Cricca, A ;

Marino, A ;

Valenti, D ;

Melotti, B ;

Amaducci, E ;

Guardigli, C ;

Lenzi, M ;

Martorana, G ;

Buli, P ;

Martoni, AA .

ANTICANCER RESEARCH, 2006, 26 (3B) :2301-2306

← 1 2 3 4 5 →